Table 3.
Second-line MDR-TB drugs used in the empiric regimens for 110 patients in the study
| Entire population (N = 110) | HIV-negative (N = 83) | HIV-positive (N = 27) | P value | |
|---|---|---|---|---|
| Kanamycin | 96 (87.3) | 78 (94.0) | 18 (66.7) | < 0.0005 |
| Capreomycin | 14 (12.7) | 5 (6.0) | 9 (33.3) | < 0.0005 |
| Levofloxacin | 86 (78.2) | 73 (88.0) | 13 (48.2) | < 0.0005 |
| Moxifloxacin | 14 (12.7) | 10 (12.1) | 14 (51.9) | < 0.0005 |
| Cycloserine | 108 (98.2) | 81 (97.6) | 27 (100.0) | 0.416 |
| PAS* | 64 (58.2) | 39 (47.0) | 25 (92.6) | < 0.0005 |
| Pyrazinamide | 106 (96.4) | 82 (98.8) | 24 (88.9) | 0.017 |
| High-dose isoniazid | 44 (40.0) | 42 (50.6) | 2 (7.4) | < 0.0005 |
| Amoxicillin/clavulanate | 2 (0.2) | 2 (2.4) | 0 (0) | 0.416 |
*
As of May of 2011, PAS was used only in HIV-positive patients, patients with advanced pulmonary disease, and patients with intolerance to cycloserine per the Haiti National Tuberculosis guidelines.